ArticleTranslational pediatrics2026
Phenotypic heterogeneity in pediatric pituitary stalk interruption syndrome: greater disease burden in the metabolic-onset phenotype.
Article in Translational pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pituitary stalk interruption syndrome (PSIS) is a rare congenital hypothalamic-pituitary disorder with marked clinical heterogeneity. Whether different presenting phenotypes reflect variations in disease burden and neurodevelopmental outcomes remains unclear. This study aimed to characterize distinct presenting phenotypes of children with PSIS and compare their diagnostic trajectories, endocrine and structural disease burden, and neurodevelopmental outcomes. Methods: In this single-center retrospective study, 31 magnetic resonance imaging (MRI)-confirmed children with PSIS were classified into a systemic-onset phenotype (n=10; hypoglycemia, cholestasis, micropenis, or adrenal crisis) and a growth-predominant phenotype (n=21; short stature or growth deceleration). Clinical characteristics, pituitary hormone deficiency profiles at diagnosis and during follow-up, MRI findings, and neurodevelopmental outcomes were compared. Exploratory Spearman analyses examined potential associations between baseline clinical and endocrine characteristics and general quotient (GQ). Results: The systemic-onset phenotype showed earlier symptom onset (0.07±0.04 Conclusions: The systemic-onset phenotype was associated with greater pituitary hormone deficiency burden at diagnosis, longer diagnostic lag, and poorer neurodevelopmental outcomes during follow-up. Initial clinical phenotype may provide a useful framework for early recognition and risk assessment, while the identification of additional pituitary hormone deficiencies during follow-up supports continued endocrine surveillance in both phenotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.